Kairos Pharma Soars 17.04% on Positive Trial Data

On September 2, 2025, Kairos Pharma's stock surged by 17.04% in pre-market trading, marking a significant rise in investor interest and confidence in the company's prospects.

Kairos Pharma is gearing up for a pivotal month in September 2025, as the company is set to report interim efficacy data from its Phase 2 trial of ENV-105. This trial is focused on patients with metastatic castration-resistant prostate cancer, a form of advanced prostate cancer. The interim safety analysis of the trial has already shown that ENV-105 is well tolerated when combined with standard-of-care hormone therapy, Apalutamide, with no dose-limiting toxicities or unexpected adverse events reported to date.

The positive safety results and the upcoming efficacy data release have positioned Kairos Pharma as a key player in the biotech sector, with investors closely monitoring the company's progress. The successful outcome of the Phase 2 trial could pave the way for further development and potential approval of ENV-105, offering a new treatment option for patients with advanced prostate cancer.